23 Apr 2020
Recent article co-published by ISARIC member Jordi Rello, Clinical Research/epidemiology In Pneumonia & Sepsis (CRIPS).
Please note that we do emphasise that treatment outside of a trial environment is dangerous and unjustified.
Also By
ISARIC
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study
- An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a rando
Related Articles
-
Reboot biomedical R&D in the global public interest
BY Soumya Swaminathan et al. -
The global spread of 2019-nCoV: a molecular evolutionary analysis
BY Domenico Benvenuto, Marta Giovanetti, Marco Salemi, Mattia Prosperi, Cecilia De Flora, Luiz Carlos J -
The art of medicine Artesunate versus quinine: the controlled trials watershed
BY Keating, Conrad -
Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population
BY Matthias Pierce, Holly Hope, Tamsin Ford, Stephani Hatch, Matthew Hotopf, Ann John, Evangelos Kontopantelis, Roger Webb, Simon Wessely, Sally McManus*, Kathryn M Abel* -
The time course of the immune response to experimental coronavirus infection of man
BY K. A. CALLOW et al.
Please Sign in (or Register) to view further.